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a  b  s  t  r  a  c  t
Radiotherapy  remains  a key  modality  in  the  palliation  of advanced  malignancy  managing  both  local
primary  tumour  effects  such  as pain  and  bleeding  as well  as the sequelae  of  metastatic  disease.  Its  role
continues  to  evolve  in line  with  advances  in radiation  technology,  which  have  facilitated  dose  escalation
and  reduced  toxicity.  Injudicious  use  of  such  advancements  has the  potential  to  magnify  the  cost  of
delivering  palliative  radiotherapy  without  achieving  signiﬁcant  gains  in  terms  of outcomes,  and  therefore
well-designed  trials to  assess  the  clinical  efﬁcacy  are  essential.  From  a policy  perspective  a  key concern
remains  the heterogeneity  in  dose  fractionation  schedules  currently  utilised  internationally  which  lack
a strong  evidence  base  and may  be  inﬂuenced  by reimbursement  policy  that  incentivises  longer,  more
complex  and  less  cost-effective  schedules.
International  consensus  is  required  on study  end-points  in palliative  radiotherapy  research  to  enable
comparison  between  case  series  and  facilitate  randomised  controlled  trial  design.  Patient  reported  out-
come  measures  should  be developed  that  capture  the  value  of  radiation  treatment  for different  indications
both  in  achieving  symptom  control  but  also  improving  quality  of  life. The  timing  and  appropriate  use  of
radiation  therapy  are  generally  guided  by  the  clinical  assessment  of  the  radiation  oncologist,  once  a  refer-
ral has  been  made.  An analysis  of  outcomes  from  national-level  epidemiological  studies  has  the potential
to  guide  appropriate  utilisation  and  identify  those  patients  most  likely  to  derive  beneﬁt  from  radiother-
apy  in different  tumour  types.  Lastly  education  and  training  remain  at  the  heart  of  reducing  inequalities
in  access  to radiotherapy  for patients  who  would  beneﬁt.  This  includes  both  radiation  oncologists  for
whom  many  training  schemes  do  not  prioritise  palliative  care  and  the wider  multidisciplinary  team  who
are involved  in the  management  of  cancer  patients  at all stages.
©  2016  Elsevier  Ltd. All  rights  reserved.ontents
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. Introduction
Approximately 50% of patients receiving radiotherapy do so
ith palliative intent [1–3], managing both local primary tumour
ffects as well as the sequelae of metastatic disease. Increasingly,
alliative regimens are also designed to achieve long term con-
rol and improve survival, in a population cohort in which disease
tage, comorbidities, performance status and patient choice may
reclude radical therapy. This has been facilitated by the introduc-
ion of radiation techniques such as high dose rate brachytherapy
insertion of radioactive sources directly into the tumour) in addi-
ion to new methods of delivering external beam radiotherapy such
s intensity modulated radiotherapy (IMRT) and stereotactic body
adiotherapy (SBRT).
This review will explore the evolution of palliative radiotherapy
n the management of cancer, including the development of new
adiotherapy dose schedules aimed at improving long term control
nd survival, and the integration of new radiation technologies. We
ill also highlight policy implications of the variation in patterns
f palliative radiotherapy delivery and the factors that inﬂuence
his: practitioner autonomy, radiotherapy access, the paucity of
vidence based management guidelines, and the reimbursement
olicy of different health systems.
. What guides the delivery of palliative radiotherapy?
The cornerstone of palliative radiotherapy is to achieve symp-
om control from the effects of the cancer. Symptoms amenable
o treatment include: pain, bleeding, neurological dysfunction and
uminal obstruction. Patients may  receive palliative radiotherapy at
iagnosis, relapse or at several points during their disease course.
alliative radiotherapy continues to evolve and it is important to
eﬁne where the patient lies on their disease pathway: patients
ith newly diagnosed locally advanced or oligometastatic cancer
ay  have different priorities and clinical aims to those nearing the
nd of life.
.1. Locally advanced disease
In patients with symptomatic locally advanced cancer, not treat-
ble radically, the aims are to improve quality of life, delay local
rogression and possibly improve overall survival. Little work
xists looking at optimum radiotherapy schedules and as a result
hose with the best performance status and longest life-expectancy
end to be offered longer schedules of radiotherapy based on indi-
idual clinician experience. In contrast, lower dose regimens of
horter duration are delivered to those with a poor performance
tatus with the aim of rapid amelioration of symptoms.
The use of complex techniques and the actual dose delivered
ill also be inﬂuenced by the site and volume of disease (e.g. prox-
mity to sensitive structures such as the spinal cord, optic chiasm
nd small bowel). For instance the spinal cord has a dose threshold
bove which the risk of subsequent myelopathy increases signiﬁ-
antly [4]. As such high dose palliative therapy may  involve greater
tilisation of more complex planning techniques such as IMRT (a
echnique that allows the high dose region to be tightly conformed
o the shape of the target, minimising damage to adjacent normal
issue) [5].
Some evidence based schedules do exist to guide palliative
adiotherapy delivery for locally advanced disease with good per- . . .  . .  . . . . .  . . . .  . . . .  . . .  . . .  . . .  .  .  . . .  . . . .  .  . . . . . . .  . . . . .  .  . . .  . . . . . .  .  . .  .  .  .  .  . . . .  . . .  . . . 27
formance status. In non-small cell lung cancer a meta-analysis
revealed no signiﬁcant difference in symptom control for patients
with different radiotherapy schedules ranging from a single frac-
tion to 6 weeks of treatment. However there may  be a small
survival beneﬁt for good performance status patients receiving
higher doses/longer courses of radiotherapy (at least 35 Gy in 10
fractions over 2 weeks), but at the expense of slightly increased
toxicity [6].
Glioblastomas of the central nervous system are incurable
tumours. However, for good performance status patients a
60 Gy fractionated schedule is recommended with concomitant
chemotherapy to improve survival [7]. However, for less ﬁt patients
either 30 Gy in 6 fractions over 2 weeks, or best supportive care
alone are the treatments of choice [8].
Patients with locally advanced or metastatic cancers of the head
and neck are also given high-dose palliative schedules, often over
20 fractions, for local control given potential issues from uncon-
trolled primary disease such as pain, bleeding, neural compression,
dysphagia, and airway compression [9].
2.2. Oligometastatic disease
The concept of the “Oligometastatic State” (OS) was ﬁrst out-
lined in 1995 [10]. It was  proposed that some tumours progress
from a localised to a widely disseminated state, via a stage of lim-
ited metastatic disease. The OS can also be “induced” with systemic
therapy (i.e. low volume residual macroscopic disease), or arise at
relapse. Palliative systemic therapy has traditionally been the treat-
ment of choice for all metastatic solid tumours, although evidence
has been accumulating for the use of focal therapy to target more
limited disease. The use of focal radiotherapy has followed on from
promising results from surgical metastasectomy for lung and liver
metastases [11,12].
Compared to surgery, radiotherapy has the advantage of being
a minimally invasive out-patient technique, requiring no anaes-
thetic, and which can target multiple lesions simultaneously,
encompassing adjacent subclinical disease. This has the potential
to change the natural history of the disease, achieving improved
local control, delayed cancer progression, and even cure in selected
cases. However whilst randomised trial evidence is awaited, there
remains limited clinical evidence to guide patient selection, as evi-
denced by signiﬁcant off-label use in the United States (Institute
of Medicine 2016). Those likely to derive beneﬁt include patients
with low volume metastatic disease (1–3 metastases, small vol-
ume), a long disease free interval from treatment of the primary
(>6 months), and favourable histology (e.g. breast cancer) [13].
Stereotactic Radiotherapy (SBRT) is rapidly becoming the tech-
nology of choice for treating oligometastatic disease. Stereotactic
describes the precise irradiation of an image-deﬁned lesion using
a high radiation dose delivered in a small number of fractions.
When applied outside the brain it is referred to as SABR (Stereo-
tactic Ablative Body Radiotherapy) [14]. This technique requires
complex methods of patient immobilisation, target localisation and
treatment planning. It is therefore more resource intensive than
conventional 2D or even 3D conformal radiotherapy [15,16]. Spe-
cialised systems do exist for delivering stereotactic radiotherapy
(e.g. Cyberknife®, and Gamma  knife®) however it is also possible
to deliver such treatments on a modern linear accelerator [17].
For brain metastases a number of treatment options exist
including neurosurgical resection, radiotherapy, molecularly tar-
al of C
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eted agents, best supportive care and combinations. A patient with
 favourable prognosis, good performance status, and a lesion less
han 4 cm in diameter may  be offered surgical resection or stereo-
actic radiotherapy, with or without whole brain radiotherapy [18].
TOG 9508 demonstrated that the addition of a stereotactic radio-
herapy boost to conventional whole brain radiotherapy improves
oth overall survival and performance status at 6 months [19].
owever for non-stereotactic “whole brain” radiotherapy, no dif-
erence has been demonstrated between 5 fraction and 20 fraction
egimens in terms of overall survival or local control [20], with
round two thirds of patients deriving some neurological beneﬁt.
SABR for lung metastases has reported 2-year local control rates
anging from 70 to 90%, with only minor toxicity (<5% grade 3 tox-
city, up to 10% pneumonitis) [21–25]. For liver metastases, SABR
ata reveals good local control rates in the region of 80% at 2-years,
lthough the majority of patients fail systemically [26].
The key to moving forward is to participate in randomised con-
rolled studies to determine the beneﬁt and cost effectiveness of
ABR. The SABR-COMET study is an example, looking at overall
urvival and quality of life in patients with 1–5 metastatic lesions
andomised to standard of care treatment with or without SABR
27].
.3. Symptom control
Palliative radiotherapy is frequently used for symptom con-
rol, often in patients approaching the end of life. In this situation
t is important to consider the delay in efﬁcacy when delivering
adiotherapy, and the possible short-term ﬂare in symptoms in
he context of the patient’s anticipated life expectancy. Factors
hat suggest a lack of beneﬁt from radiotherapy include immi-
ent death, multiple progressive symptoms, anticipated side effects
eing greater than the symptom being palliated, and poor tolerance
f the required journeys for treatment. Clinicians may  also advise
gainst re-treatment based on exceeding the safe normal tissue
olerance constraints. Depending on the healthcare model being
onsidered, cost, availability and communication between the pal-
iative care team and the radiotherapy team may  also inﬂuence
eferral patterns [28].
Hypofractionated regimens, delivering a low total dose [29],
re typically chosen with the aim of achieving rapid amelioration
f symptoms at primary or metastatic sites [9,30–32]. They are
enerally well tolerated, even in patients with poor performance
tatus, and are convenient and cost effective. However, there is
arked variation in their use internationally [33]. In the UK the
oyal College of Radiologists has published guidelines on opti-
al  dose fractionation schedules according to tumour type and
reatment intent [9]. However these recommendations are largely
ased on single centre retrospective case series given the paucity
f randomised control trials evidence [34]. However, some notable
xceptions exist.
For lung cancer short course regimens (17 Gy in 2#) have
emonstrated equivalent efﬁcacy (symptom control and survival)
o longer regimens in patients with poor performance status [35]. In
esophageal cancer dose fractionation regimes considered include
0 Gy in 10 daily fractions, 27 Gy in 6 fractions (treating three times
 week) and 20 Gy in 5 daily fractions [36,37]. The addition of High
ose Rate brachytherapy has been found to improve symptom
esolution and potentially prolong survival by achieving dose esca-
ation [37]. In bladder cancer, a fractionation schedule of 21 Gy in
 fractions delivered on alternate weekdays over one week is cur-
ently advocated based on a MRC  trial, which found no differences
n outcomes when compared with 35 Gy in 10 fractions [38].
In cervical cancer one study demonstrated the effectiveness
symptom control) of delivering “quad shots” which involve treat-
ng the patient twice a day for two days to a total dose of 14–16 Gyancer Policy 10 (2016) 21–29 23
[39,40]. A similar strategy has been advocated for head and neck
cancer based on the results of a phase II study [41].
Current international evidence suggests that palliative radio-
therapy may  be being delivered inappropriately. A number of US
studies have shown that up to 50% of patients die before comple-
tion of the prescribed radiotherapy schedule [42–44]. Furthermore
a signiﬁcant proportion of patients receiving radiotherapy within
the last 30 days of life had multi-fraction treatment. Such practice
in the last weeks of life may  delay palliative care input, end of life
planning and appropriate symptomatic management [28].
It has been suggested that prognostic models could guide both
doctors and patients when making decisions about radiother-
apy near end-of-life. Doctors tend to be over-optimistic when
predicting the life expectancy of patients referred for palliative
radiotherapy [45–47] and patients who  are overly optimistic in
their understanding of their cancer are likely to receive more
aggressive treatment [48]. Given that a signiﬁcant proportion of the
total cost of cancer treatment is accrued in the last 30 days of life
with little if any impact on outcome [49], it is clear that evidence-
based guidelines are essential for optimum patient management.
Models have been proposed, but are yet to be adopted into rou-
tine practice due to lack of physician engagement and deﬁcits in
training. It could be argued that the models are too simplistic and
that more profound changes could be achieved by cultural changes
in how palliative care is approached, and changing ﬁnancial incen-
tives to encourage appropriate practices of care, as will be discussed
[50].
Whilst evidence based guidelines have focussed on dose and
fractionation, the actual decision to refer for radiotherapy or initi-
ate treatment is at the discretion of the individual practitioner. It is
therefore based largely on their own  personal experience and inter-
pretation of the likely beneﬁt and appropriateness of treatment.
3. Policy issues in palliative radiation oncology
3.1. Variation in access to palliative radiotherapy
Evidence from epidemiological studies has demonstrated that
not all patients who  may  beneﬁt from palliative radiotherapy are
receiving it. An analysis of the national radiotherapy dataset for
England between 2009 and 2011 demonstrated a trend towards
less use of both radical and palliative radiotherapy in the more
socioeconomically deprived groups [1].
In the US a study using data from the SEER database (Surveil-
lance, Epidemiology, and End Results-Medicare linked database)
identiﬁed 51,610 patients with stage IV lung, prostate, breast or
colorectal cancer between 2000 and 2007 [51]. The results demon-
strated that black men  with prostate cancer and lung cancer were
20% and 28% less likely respectively to receive palliative radiother-
apy compared to white men.
Another SEER study analysing rates of palliative radiotherapy
use in 63,221 patients demonstrated on multivariate analysis that
compared to patients aged 66–69, those aged 70–74, 75–79, 80–84,
and over 85 had a 7%, 15%, 25%, and 44% decreased rate of receiving
palliative radiation, respectively (all p < 0.0001) [52]. Other factors
associated with lower palliative radiotherapy included increased
travel time to a radiotherapy centre, diagnosis at a non-specialist
cancer centre and nursing home residence [2,53].
Although epidemiological studies have been valuable in elicit-
ing the factors associated with differential utilisation in palliative
radiotherapy this data is limited as it cannot account for differences
in disease biology, patient presentation, physician practice and pat-
terns of progression, which may  all explain a patient’s decision
to forgo radiotherapy. Possible reasons may  therefore be gleaned
from an analysis of the wider literature. For instance we  know
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hat the relative survival of elderly patients with cancer is sig-
iﬁcantly worse compared to younger persons. The reasons are
ultifactorial and include, advanced stage at diagnosis, comor-
idities, and barriers to accessing cancer services [54–56]. There
s strong evidence that elderly cancer patients are more likely to be
nder-treated (even after adjustment for performance status and
ther case mix  criteria) with many not considered for therapies
uch as chemotherapy or surgery [57,58]. Training and appropri-
te utilisation of geriatric screening tools may  improve access of
lderly patients to palliative radiotherapy [59].
As well as for palliative radiotherapy, ethnic differences have
een noted in utilisation of advanced radiation technologies and
ystemic therapies [60,61]. Potential factors include communica-
ion difﬁculties (language/cultural), and differences in inherent
umour biology [51,62]. Race as with age may  also act as a proxy
or socioeconomic status, which affect the ability to access and pay
or care [63].
Geographical location is also an important factor with sev-
ral studies demonstrating a correlation between travel time and
ptake of cancer treatment (surgery, radiotherapy, chemother-
py) in both the radical and palliative setting [64,65]. This is in
art attributable to the increasing centralisation of cancer services,
owever this has had the resultant effect of increasing travel times
or patients and may  in fact exacerbate inequities in access and
urvival outcomes [66–68].
Differential access to palliative radiotherapy may  only be over-
ome through education of practitioners both in the hospital and
ommunity setting. There is evidence demonstrating the positive
ffect of primary care physician education on referral patterns
or palliative radiotherapy [69]. Patients also need to be educated
peciﬁcally about the possible sequelae of metastatic disease and
ndications for self-referral to a specialist
A lack of radiation oncology engagement with palliative care
ractice has been identiﬁed in a US study. Reasons included limited
nancial reimbursement, emotional burden of care, insufﬁcient
raining and knowledge and the reluctance to provide shared care
70]. The onus is on the professional bodies to initiate a change in
ulture to address these attitudes.
.2. Reimbursement policy and use of palliative radiotherapy
Goals of palliative radiation therapy should be that the treat-
ent is effective (palliating symptoms and improving quality of
ife), overall treatment time should be short, convenience for the
atient maximised and costs minimised [71]. However a review
f fractionation schedules internationally for a variety of pallia-
ive indications suggests that we are not adhering to these core
rinciples. A prescient example is the case of uncomplicated bone
etastases.
Trial data has conﬁrmed the equivalence of single fraction
nd multiple fractions of radiotherapy in palliating pain related
o uncomplicated bone metastases [72,73]. Furthermore single
raction therapy has been shown to be more cost effective even
hen accounting for the higher rates of re-irradiation compared
o multi-fraction treatment [74]. This prompted the development
f consensus guidelines from the American Society for Radiation
ncology (ASTRO) recommending single fraction therapy as the
referred treatment for uncomplicated bone metastases and that
o more than 10 fractions should be delivered [30]. Despite this,
ulti-fraction treatment remains the most popular schedule inter-
ationally [33,75,76].
One study in the US looking at fractionation schedules for men
ith prostate cancer treated for bone metastases found that 3.3%
nly received single fraction treatment, with 50% receiving greater
han 10 fractions [77]. Key differences were noted between aca-
emic and both private and community facilities with radiationancer Policy 10 (2016) 21–29
oncologists working at the latter signiﬁcantly more likely to deliver
multi-fraction treatment [76].
Further analysis demonstrates clear regional differences
between practices of care in the US compared to Europe, Canada and
Australia [75]. In the Fairchild study respondents trained in parts of
Canada or Europe were more than twice as likely to use single frac-
tion regimens, whereas respondents trained in the USA were up to
80% less likely to use a single fraction [33,78]. Unfortunately such
variations have a direct impact on the patient in terms of quality of
life and convenience of treatment. Equally from a health policy per-
spective inefﬁcient practices of care are still continuing which affect
both the workload faced by radiotherapy departments and con-
tribute to escalating costs of treatment for the health care system
[79].
One of the key factors underpinning this variation is the model of
reimbursement within individual countries. Lievens has previously
[80] reviewed the impact of reimbursement models across Western
Europe on fractionation schedules utilised for palliative radiother-
apy. A clear differential was seen between countries employing a
fee for service model where each component of radiation therapy
delivery is reimbursed (simulation, planning, treatment delivery)
e.g. Germany and Switzerland, and those employing a global bud-
get or case based system of reimbursement whereby departments
are reimbursed per patient or a full treatment course e.g. Spain and
The Netherlands.
A fee for service model was associated with an increased like-
lihood of using multi-fraction schedules for palliation. There is
therefore a disincentive for employing efﬁcient practices of care.
Of note, the greater use of single fraction schedules in US academic
institutions may  relate to the fact that many physicians are salaried
in these institutions and gain no ﬁnancial beneﬁt from delivering
more fractions. More clearly needs to be done especially given that
up to 60% of variation in costs of radiotherapy in the US relate to
geography, practice type and individual radiation therapy provider
[81].
A further concern is the interface between hospice care and radi-
ation oncology. A survey from the US in the early 2000’s found that
less than 1% of hospice patients are referred for radiotherapy [82].
Reasons include, the inconvenience of repeated journeys, educa-
tion deﬁciencies, life-expectancy and most importantly expense.
This has been exacerbated by the predominant utilisation of multi-
fraction schedules which can cost upward of $5000 US  dollars
to deliver, and can dissuade referral due to their inconvenience
[33,77]. Furthermore these costs are charged direct to the hos-
pice which has an average daily reimbursement rate of $150 US
dollars. A study evaluating the impact of a rapid access radiother-
apy clinic offering affordable radiotherapy and minimising waiting
times and duration of treatment demonstrated increased referral
activity from hospices [83].
In reality country-speciﬁc reimbursement models cannot be
wholly categorised and usually employ more than one model. For
instance in the UK, there has been a move to a reimbursement
per attendance or procedure model whereby treatments delivered
are reimbursed according to a ﬁxed tariff based on reference costs
that are deﬁned nationally [84]. Whilst this may stimulate use of
longer fractionation schedules, a driver for continued efﬁciency is
the need to maintain capacity and reduce waiting lists [85,86] to
ensure palliative patients are treated within 14 days. In addition
patients requiring the treatment of two  sites on the same day are
still reimbursed as a single attendance.
3.3. Reimbursement policy in the era of technological evolutionThe costs of delivering radiation therapy in both the radical and
palliative setting continue to increase [87]. Whilst palliative treat-
ment can be delivered quickly, cost-effectively and with low rates of
al of C
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oxicity using conventional 2D radiotherapy (utilising x-ray local-
sation and simple beam arrangements), culturally we  are moving
o use of high dose palliation with more advanced technology.
This has signiﬁcant ﬁnancial implications. SBRT for bone metas-
ases costs up to ten times more per treatment [88] when compared
ith single fraction therapy delivered conventionally and is not
ost-effective. However there is an increasing argument to use
his modality when life expectancy is estimated to be beyond 12
onths, for re-treatment where ﬁelds are likely to overlap sensi-
ive structures or in difﬁcult to treat areas such as pelvic recurrence
nd para-aortic disease [89–91]. Likewise for the management of
rain metastases, hippocampal sparing whole brain radiotherapy
sing IMRT may  reduce the late sequelae of treatment, in particular
eurocognitive decline [92]. However in most instances the dosi-
etric advantages of newer technologies are not applicable in the
alliative care setting.
Careful patient selection is imperative and we need to avoid a
ulture of merely using new technology based on their intuitive
eneﬁts in the absence of objective data from randomised con-
rol trials. Equally reimbursement policies should be realigned to
is-incentivise utilisation of non-evidence based modalities or dose
ractionation regimes (e.g. through the introduction of value based
ser charges [16]).
The provision of evidence based guidelines, use of health
echnology assessment for evaluating new high cost radiation tech-
iques, and strong reimbursement policy is therefore essential to
ncourage rational utilisation of new technologies and promote
fﬁcient practices of care [93]. “Coverage with evidence develop-
ent” has been considered to be one mechanism of ensuring access
o new technologies which have capacity to improve outcomes
hilst collecting data to inform the evidence base about its utility
n a real world population [94]. This is the premise for the current
ssessment of SABR in the NHS [95].
.4. Education and multidisciplinary management in palliative
ncology
Appropriate training and education is also a key aspect of ensur-
ng implementation of evidence based guidelines. A recent survey
f Radiation Oncology residents across the US noted key deﬁcien-
ies in palliative care competencies (e.g. symptom management,
are coordination) and most viewed palliative radiation oncology
raining as inadequate and wished for greater training in these areas
96].
Integrating palliative care into radiation oncology has been
ttempted through the creation of rapid access palliative radio-
herapy clinics (Rapid response Radiotherapy program) which were
rst developed in Canada [97]. The clinics have reduced waiting
imes for radiotherapy and ensured multidisciplinary assessment
nd management of complex patients, focussing on quality of life
nd symptom control. This model continues to evolve and many
xamples exist across North America [98].
In the US, although sporadic in their implementation, these
ntegrated palliative care models have helped to improve both
adiotherapy access and the proportion of patients treated with
ingle fraction radiotherapy according to evidence based guide-
ines [99]. They have also reduced the differential practice patterns
etween academic centres and community centres. Such models
rovide a forum for knowledge transfer and training of the wider
ultidisciplinary team as well as helping to support patients and
heir families..5. Trial endpoints for palliative radiotherapy
Trials within palliative radiation oncology have focussed on the
se of differing dose fractionation schedules, combined modalityancer Policy 10 (2016) 21–29 25
therapies (e.g. chemoradiation), new radiation delivery techniques
and deﬁning new indications for treatment (e.g. asymptomatic
oligometastases). The list of potential confounding factors is vast
given the heterogeneity of disease. From the patient perspec-
tive, differences in the extent of functional impairment, impact on
quality of life, burden of metastatic disease, performance status,
associated comorbidities and extent of previous therapy make eval-
uation of the efﬁcacy of new radiotherapy techniques and regimes
challenging.
As a result the evidence base has largely emanated from sin-
gle centre retrospective case series which are limited due to poor
accounting for case mix  variables (age, comorbidity, performance
status) and frequently appear to have better outcomes than the
benchmark ﬁndings from studies in broader unselected, popula-
tions. It is therefore imperative that selection bias is overcome
by undertaking randomised trials or well-constructed prospective
studies that ensure adequate collection of case mix variables and
which use validated end points [100]. Whilst there are inherent
challenges in designing radiotherapy trials given the rapid software
and hardware developments and the variation in practices of care
between centres [101], many of these issues do not apply in the
palliative setting.
An area of contention is how best to deﬁne appropriate trial
end-points in palliative radiation oncology. As with systemic ther-
apies, the goal posts are increasingly moving, with end-points such
as overall survival (OS) and progression free survival (PFS) increas-
ingly being utilised [102]. This despite numerous qualitative studies
involving patients with advanced malignancy demonstrating that
improved quality of life is most important goal of therapy [103,104].
Part of the issue is that the term palliative from a radiation oncol-
ogy research perspective has become very broad and essentially
encompasses patients with life expectancies in the region of weeks
to those who  may  survive in excess of 5 years. This confusion is
making the selection of end points for trials much harder and the
undertaking of systematic reviews more methodologically chal-
lenging. An analysis of trials comparing single fraction and multiple
fraction treatments for bone metastases [105] found that a major
reason for the different conclusions concerning the effectiveness
of alternative fractionation schedules was  due to the variability in
end points used in the studies. As a result consensus guidelines
were produced in order to formulate a framework for palliative
radiotherapy trials in patients with bone metastases [106]. Simi-
lar guidelines for alternative disease sites are imperative to enable
meaningful comparison between trials and help deﬁne new stan-
dards of care.
Progress has been made in the development of quality of life
assessment tools that are not only cancer speciﬁc but are directed
to individuals with advanced disease such as the EORTC QLQ-C30,
the QLQ-C15-PAL scales [107]. A bone metastasis speciﬁc quality of
life tool has also been developed − EORTC QLQ-BM22 [108]. How-
ever despite this progress, frequent criticisms of patient reported
outcomes measures (PROMS) include both their lack of speciﬁcity
for radiotherapy related treatment effects and their inadaptabil-
ity when accounting for rapid changes in technology, thus making
comparison difﬁcult with historical studies [109]. Some studies use
a number of different questionnaires to get the balance between
speciﬁcity and generalisability [110] however a number of ques-
tions may  overlap resulting in differences in PROMS results from
the same study [111].
Michael Porter has written eloquently about the need for value
based end-points which go beyond traditional methods of assess-
ment including OS, PFS and quality of life [112]. Consideration
should therefore be given to assessing alternative outcomes fol-
lowing palliative radiotherapy such as (1) frequency and duration
of inpatient admission; (2) frequency of out-of-hours palliative care
and GP consultations; (3) return to work; (4) duration of functional
2 al of Cancer Policy 10 (2016) 21–29
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Box 1 Key recommendations to address current policy
issues in palliative radiotherapy
• Professional bodies to continue to deﬁne standards of care in
palliative radiotherapy, speciﬁcally dose fractionation sched-
ules.
• Encourage greater use of health technology assessment pro-
cesses for the evaluation of new radiation techniques in the
palliative setting.
• Reconﬁgure reimbursement policy to incentivise cost-
effective palliative radiotherapy practices.
• Use of epidemiological data to enhance our understanding
of the outcomes of patients treated with palliative intent to
ensure better selection of patients to avoid mortality during
treatment.
• Validate and integrate prognostic models into clinical prac-
tice to guide utilisation of radiotherapy towards the end of
life.
• Consensus guidelines to be developed on trial end-points
in different tumour types to facilitate comparison between
outcomes from palliative radiotherapy trials.
• Development of specialist palliative care multidisciplinary
teams to ensure that suitable patients get rapid access to
all appropriate treatment modalities, encourage evidence
based practices of care, and improve training and education
of all team members including junior staff.6 A. Aggarwal, S. Hughes / Journ
ndependence. These end-points may  help to better evaluate the
tility of palliative radiotherapy.
.6. Evidence framework to guide utilisation of appropriate
alliative modality
It is important that evidence based guidelines enable clinicians
o select the appropriate palliative strategy (e.g., systemic treat-
ent, radiotherapy, best supportive care) for managing advanced
isease. For example a recent meta-analysis reviewed all trials
omparing the use of EGFR tyrosine kinase inhibitors with cranial
rradiation in patients with brain metastases secondary to EGFR
utant non-small cell lung cancer [113]. As discussed this is chal-
enging especially in terms of deﬁning appropriate trial end-points
nd selecting patient cohorts for comparison. However such com-
arisons are necessary given the potential role of radiotherapy
n managing patients with oligometastases who previously would
ave been referred for systemic therapy. If found to be of similar
fﬁcacy, radiotherapy may  be considered to be advantageous given
hat apart from fatigue, its systemic effects are minimal and that
reatment duration is much shorter [29]. Similar comparisons need
o be performed in other indications such as palliation of dyspha-
ia from advanced oesophageal cancer, which may be amenable to
reatment with external beam radiotherapy, chemotherapy, endo-
copic procedures and HDR Brachytherapy.
.7. The value of audit in deﬁning practice of care
In the UK, currently all deaths within 30 days of chemother-
py and surgery are audited and subject to retrospective case note
eview [114]. A similar system has not as yet been employed for
adiotherapy but has been recommended as a clinical indicator of
voidance of harm in radiotherapy. There are caveats in using such
ndicators. For instance it may  be impractical given the difﬁculty
n assessing life expectancy. Furthermore the burden of treatment
ith a single fraction of radiotherapy given the potential pallia-
ive beneﬁts is minimal. However auditing 30-day mortality does
rovide insights into patterns of care which can guide appropriate
tilisation of palliative radiotherapy.
A large single centre study in the UK reviewed 30-day mor-
ality rates following palliative radiotherapy for 14,972 palliative
pisodes, between Jan 2004 and April 2011 and found 30-day mor-
ality rates of approximately 12.3% [115]. Mortality rates were
ower in those receiving multi-fraction treatments suggesting that
ase selection was largely appropriate. Another interesting ﬁnd-
ng was the higher rates of 30-day mortality for speciﬁc tumour
ypes in patients receiving radiotherapy for brain metastases (e.g.,
elanoma and carcinoma of unknown primary). Further studies
re therefore essential to guide appropriate patient selection for
alliative radiotherapy and optimise end of life care. It will also help
o support the development of trials randomising patients between
est supportive care and radiotherapy.
It is also imperative that tumour speciﬁc registries and national
udits of processes and outcomes of cancer care [116] are set up in
rder to collect population based data which can be benchmarked
gainst best practice to ensure that inequities in access and varia-
ions in practice are highlighted and subsequently addressed [117].
hey also help to deﬁne new standards of care, especially where
imited randomised trial evidence exists to support the use of one
echnology over another.. Conclusions
Radiotherapy is an established and effective treatment modal-
ty in the palliation of symptoms associated with advanced cancer.However its role continues to evolve in line with advances in radia-
tion technology. The evidence base remains in its infancy and much
more needs to be done to deﬁne standards of care in both high and
low dose palliation. The latter continues to be the main indication
of radiotherapy in advanced disease.
Although clinical acumen is a valuable resource, its individuality
has the potential to result in inequalities in care. Multidisciplinary
team working, and discussion of patient management in complex
cases has the potential to minimise variations in decision making
with respect to the utilisation of radiotherapy. In addition, guidance
is also required for the wider multidisciplinary team regarding the
utility of radiotherapy and beneﬁts of a timely referral.
Given the heterogeneity of international practice, reimburse-
ment policy needs to align with the needs of the patient as many
of the current fractionation schedules used for routine indications
are both inefﬁcient and are delivered at greater inconvenience to
the patient. Likewise given the complexity of managing advanced
disease, training and education of all members of both the oncology
and palliative care team are necessary in order to ensure radiother-
apy is instituted within the appropriate timeframe and delivers
outcomes in keeping with patient’s wishes. The creation of spe-
cialist palliative radiotherapy multidisciplinary teams will facilitate
this and improve access to radiotherapy services.
Greater research prioritisation needs to be afforded to devel-
oping high-value fractionation schedules for the management of
advanced disease that are able to palliate symptoms rapidly, min-
imising toxicity and maximising convenience to the patients. In
the future this may  be achieved through multi-modality therapy or
use of new radiation techniques but trial evidence ideally needs
to inform this. Currently much of the evidence base is derived
from single centre retrospective case series where comparison is
often not possible due to the use of non-standardised end points.
Given the inherent challenges of designing randomised control tri-
als in this cohort, coverage with evidence development, if correctly
implemented using standardised end-points and rigorous collec-
tion of case-mix variables, offers a potential alternative.
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